Rob Arnold
수석부사장 (EVP)
Expertise:
"유럽, 북미, 아시아 전역에서 30년 이상 컨설팅 및 리더십 경력을 쌓은 Rob Arnold는 생명과학 분야에서 가장 까다로운 비즈니스 상황에 대한 창의적인 솔루션을 개발한 바 있습니다. R&D 포트폴리오, 생명공학 대기업의 방향 재설정 등 혁신과 전환 업무를 담당하고 있습니다.
Rob은 업계 포럼, 경영대학원, 전문 협회에서 생명과학 분야 전략에 대한 강연을 하고 있으며, 전문 논문도 여러 편 출간한 바 있습니다.
미국 다트머스대학교 에이머스턱비즈니스스쿨에서 MBA 학위를 받았고 캠브리지대학교에서 석사 학위를 받았습니다."
Articles by Rob Arnold
Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare
Authors: Prachi Singh, Senior Consultant; Robin Arnold, EVP, APAC Consulting Unlock the future of healthcare with our white paper, “Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare.” Discover the essential components of pricing AI/MedTech solutions and crafting compelling value propositions that resonate with stakeholders, including payers, patients, and physicians. Explore real-world examples, […]
Navigating the Patient Journey: Understanding, Challenges, and Solutions in Patient Journey Mapping
EVERSANA’s APAC Authors: Ankit Kulshrestha, Robin Arnold This POV explores the intricacies of Patient Journey Mapping, detailing its significance, challenges, and solutions. Patient journey mapping is a comprehensive discipline that traces a patient’s entire healthcare journey, from initial symptoms to treatment and beyond. Understanding this journey is imperative for pharmaceutical companies, enabling them to address challenges […]
Reframing the Challenges of Access and ROI
Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see evidence of corporate responsibility, for which pharmaceuticals’ surrogate measure is access. While companies such as Novo Nordisk and UCB […]
WEBINAR: Sustainability in Pharma: Access and Financial Returns
In addition to the global disruption caused by COVID-19, pharma faces additional pressure to adopt digital technologies, transform long-standing business practices, and accelerate timelines to deliver value for HCPs and patients. Not to mention, the specialty pipeline continues to grow, but therapies for rare diseases are facing significant access challenges. In this webinar, EVERSANA’s Rob […]
How Do You Know Your Portfolio Process Is Adding Value?
In 1998, Rob Arnold, Executive Vice President, teamed with some colleagues to publish an article in the Harvard Business Review that highlighted the practical results obtained by applying modern R&D portfolio thinking to SmithKline Beecham’s late-stage assets. SB publicly claimed that the review process had added $2.6 billion in value to the corporation. That team […]